KSI-101 provides continued disease control for MESI patients, as evaluated at Week 12 with the effect of 3 monthly doses 200 250 300 350 400 450 500 550 Mean Change in OCT CST and absolute CST achieved by Week 12 Vamikibart KSI-101 Dryness Mean Change Baseline Legend DOVETAIL 1 PEACHTREE 2 MERIT 3 APEX 4 -126 -189 -185 -16 -139 -174 -77 -209 -264 -199 86 -73 OCT CST, microns 0.25 mg n=12 1 mg n=12 2.5 mg n=13 2.5 mg n=9 5 mg n=8 10 mg n=10 Sham n=64 RBZ n=69 Anti-IL-6 Anti-VEGF Xipere n=96 Ozurdex n=76 RBZ n=69 MTX n=76 1. Sharma S, et al. A Novel Intravitreal Anti-IL-6 Monoclonal Antibody for Uveitic Macular Edema (UME): Preliminary Results From the Phase 1 DOVETAIL Study. Presented at the American Society of Retina Specialists, Seattle, WA, July 2023. Mean values adapted from CST graph on slide 10. 2. Yeh S, et al. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020 Jul;127(7):948-955 3. Acharya NR, et al. The MERIT Trial Results. Ophthalmology. 2023 Sep;130(9):914-923. Mean values adapted from Figure S3 (supplemental). 4. Preliminary results. As the APEX study is ongoing, final results may be different due to additional data collection or data cleaning. Includes only patients in the per protocol set that completed the Week 12 visit by the cutoff date of 14-Jul-25 and meet all the eligibility criteria. Excludes one patient in the 10 mg dose with a significant epiretinal membrane at baseline (exclusion criterion) For illustrative purposes only. Not a head-to-head comparison. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies.